Table 2.

Summarizes other possible therapeutic compounds in SARS-CoV-2 infection.

Drug	Mechanism of action	Trial/Phase
Recombinant form of the ACE2 (Khan et al., 2017)	Inhibition of viral adhesion to host cells
Camostat mesylate (Kawase et al., 2012; COVID-19 Clinical Trials, 2020)	Inhibition of viral entry by inhibition of TMPRSS2	NCT04321096 Phase1/2
Favipiravir (COVID-19 Clinical Trials, 2020; Dong et al., 2020b)	RNA-dependent RNA polymerase inhibition	NCT04358549, Phase 2
Eculizumab (Gralinski et al., 2018; COVID-19 Clinical Trials, 2020)	C5 complement inhibitor	NCT04288713
Neutralizing Antibodies (47D11) (Wang et al., 2020d)	Interaction with Spike protein
Ivermectin (Caly et al., 2020; COVID-19 Clinical Trials, 2020)	Inhibition of in vitro replication	NCT04390022, Phase 2
Corticosteroids: Methylprednisolone (Russell et al., 2020; Wu et al., 2020), Dexamethasone (RECOVERY trial, 2020)	Immunosuppression	NCT04273321, NCT04381936 Phase 2/3